Vienna, Austria,
2012-08-23 19:57
(4055 d 22:12 ago)

Posting: # 9099
Views: 3,247

 FDA: GDUFA / D-U-N-S Number [BE/BA News]

Dear all,

THX to Ohlbe who suggested to come up with this goodie.

Go for it if #4 is applicable* (which was not required before); otherwise the penalty is nasty:

Under GDUFA, if a facility fails to self-identify, all FDF or API products manufactured at the facility and all FDFs containing APIs manufactured at the facility will be deemed misbranded. It is a violation of federal law to ship misbranded products in interstate commerce or to import them into the United States. Such violations can result in prosecution of those responsible, injunctions, or seizures of the misbranded products. Products that are deemed misbranded because of failure of the facility to self-identify are subject to being denied entry into the United States.

  • The following types of generic industry facilities, sites, and organizations are required to self-identify with FDA:
    #4. Bioequivalence (BE)/bioavailability (BA) sites that are identified in a generic drug submission and conduct clinical BE/BA testing, bioanalytical testing of samples collected from clinical BE/BA testing, and/or in vitro BE testing.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
UA Flag
 Admin contact
22,763 posts in 4,775 threads, 1,628 registered users;
20 visitors (0 registered, 20 guests [including 2 identified bots]).
Forum time: 18:10 CEST (Europe/Vienna)

Restlessness is discontent –
and discontent is the first necessity of progress.
Show me a thoroughly satisfied man 
and I will show you a failure.    Thomas Alva Edison

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz